National Institutes of Health, a Component of the US Dept. of Health & Human Services

Joost J Oppenheim

De Yang

Michael Bustin

Kouji Matsushima

Ettore Appella

Teizo Yoshimura

Edward J Leonard

Philip M Murphy

Stephen D Showalter

Dimiter Stanchev Dimitrov

Zhongyu Zhu

William J Murphy

Edward A Sausville

O M Zack Howard

Ji Ming Wang

Joseph John Barchi, Jr

Ji-Liang Gao

WangHua Gong

Yingying Le

Ji-Ming Wang

Bao Qun Li

Zhen Han

Thomas Rogers

Xin Chen

Wang Hua Gong

Shao-Bo Su

A human monoclonal antibody that specifically binds tumor necrosis factor receptor 2 (TNFR2), and a defucosylated form of the antibody, are described. The TNFR2-specific antibody was isolated from a human scFv phage display antibody library. The disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2CD4T regulatory cells in a dose- and time-dependent manner. Methods of using the TNFR2 antibodies, such as for tumor immunotherapy, are described.

Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.

Therapeutic antitumor combination of a TLR4 ligand with other treatments

A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants

The present invention relates to the discovery that T20/DP178, T21/DP107, and fragments thereof interact with members of the formyl peptide receptor family and thereby modulate cell migration and activation. Novel biological tools, prophylactics, therapeutics and methods of use of the foregoing for modulating an inflammatory response are disclosed.

T20/DP178 is an activator of human phagocyte formyl peptide receptors

The present invention relates to the discovery of molecules that inhibit viral infection and promote a host immune response to a pathogen. More specifically, the invention disclosed herein concerns molecules that interact with a FPR class receptor, inhibit HIV infection, and stimulate an inflammatory response in a subject. Embodiments of the invention include biotechnological tools, prophylactics, therapeutics, and methods of use of the foregoing, for the study, treatment, and prevention of HIV infection and the induction of an inflammatory response in a subject.

Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection

A method of using a ureido derivative of a poly-4-amino-2-carboxy-1-methyl pyrrole or a pharmaceutically acceptable salt thereof to inhibit inflammation, particularly non-TNF-&agr; dependent inflammation, in a mammal.

Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Nucleic acids encoding a novel neutrophil chemotactic factor

Growing community of inventors

Bethesda, MD, United States of America

Joost J Oppenheim